•
Dec 31, 2020
Reviva Q4 2020 Earnings Report
Reported financial results for 2020 and provided a corporate update.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $3.8 million for the year ended December 31, 2020. The company closed a merger with Tenzing Acquisition Corp in December 2020 and is planning a Phase 3 study of RP5063 in mid-2021, assuming fundraising goals are achieved.
Closed merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market.
Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved.
Completed a Phase 2 study of brilaroxazine in patients with acute schizophrenia and schizoaffective disorders.
Granted Orphan Drug Designation for brilaroxazine for the treatment of PAH and IPF.